红日药业：股东姚小青计划减持不超过约4694万股

Group 1 - The core point of the news is that Hongri Pharmaceutical announced a share reduction plan by major shareholders and senior management, indicating potential changes in ownership structure [1] - Shareholder Yao Xiaoqing, holding approximately 300 million shares (10% of total shares), plans to reduce holdings by up to 46.94 million shares (1.5624% of total shares) within three months after the announcement [1] - Senior management members Chen Ruiqiang and Zhang Kun plan to reduce their holdings by up to 170,000 shares (0.0056% of total shares) and 230,000 shares (0.0077% of total shares) respectively, also within three months after the announcement [1] Group 2 - For the fiscal year 2024, Hongri Pharmaceutical's revenue composition is as follows: Traditional Chinese medicine formula granules and decoction pieces account for 46.15%, finished drugs 24.72%, medical devices 19.39%, excipients and raw materials 8.33%, and other industries 1.42% [2] - As of the latest report, Hongri Pharmaceutical has a market capitalization of 11.4 billion yuan [3]